NaCl 0.9% ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 39 | Toxic epidermal necrolysis | 1 |
39. Toxic epidermal necrolysis
Clinical trials : 13 / Drugs : 19 - (DrugBank : 8) / Drug target genes : 11 - Drug target pathways : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02739295 (ClinicalTrials.gov) | July 2016 | 4/4/2016 | G-CSF in the Treatment of Toxic Epidermal Necrolysis | Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis | Stevens - Johnson Syndrome | Drug: recombinant granulocyte - colony stimulating factor;Drug: NaCl 0.9% | University of Liege | NULL | Recruiting | 18 Years | N/A | All | 10 | Phase 4 | Belgium |